Novozymes Biopharma has entered a collaboration with Janssen Research & Development, LLC under which Janssen will evaluate Novozymes’s engineered albumin-based VELTIS technology for potential drug candidates. Novozymes' VELTIS technology represents a series of engineered human albumins that in combination with a drug candidate, offers the potential for control of the therapeutic half-life, which allows for reducing the dosing frequency of drugs from daily to every two weeks or monthly.
"We are delighted to be working with Janssen on this important collaboration," said Svend Licht, senior director, Novozymes Biopharma. "The VELTIS half-life extension technology can be linked to a broad range of drug candidates and the agreement is central in our continued strategy to demonstrate its potential to facilitate greater control across many therapeutic fields. The VELTIS platform is a transformative technology that offers real potential to revolutionize the delivery of treatments. Working with partners across a wide-range of medical conditions, we are continuing to highlight the benefits of the solution in improving the lives of patients."